Improved survival in chronic lymphocytic leukemia in the past decade: A population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden

Haematologica

Volumn 94, Issue 9, 2009, Pages 1259-1265

  Kristinsson, Sigurdur Yngvi ^a   Dickman, Paul W ^b   Wilson, Wyndham H ^c   Caporaso, Neil ^c   Björkholm, Magnus ^a   Landgren, Ola ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chronic lymphocytic leukemia; Older age; Population based; Prognosis; Sex; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; SWEDEN;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN;

EID: 70349094507     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.007849     Document Type: Article

References (31)

1. Socialstyrelsen. Cancer Incidence in Sweden 2006. Stockholm, Sweden; 2007.
2. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004.
3. Lin TS, Grever MR, Byrd JC. Changing the way we think about chronic lymphocytic leukemia. J Clin Oncol 2005;23:4009-4012 (Pubitemid 46211304)
4. Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 2000;27:587-597 (Pubitemid 30791830)
5. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432-1438 (Pubitemid 26161205)
6. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325
7. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757
8. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-798 (Pubitemid 350002879)
9. st century. Blood 2008;111:4916-4921
10. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809-819 (Pubitemid 350115721)
11. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001;92:1325-1330
12. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999;86:2684-2692
13. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371:1017-1029
14. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-313
15. Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 2007;121:2260-2266
16. Henson DE, Ries LA. The relative survival rate. Cancer 1995;76:1687-1688
17. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982;38:933-942
18. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506-1514
19. Idestrom K, Kimby E, Bjorkholm M, Mellstedt H, Engstedt L, Gahrton G, et al. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone. Eur J Cancer Clin Oncol 1982;18:1117-1123 (Pubitemid 13196516)
20. Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991;9:770-776
21. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414-1420 (Pubitemid 32202548)
22. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773
23. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574
24. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164 (Pubitemid 32366969)
25. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088 (Pubitemid 46211313)
26. Dreger P, Brand R, Michallet M. Autologous stem cell transplantation for chronic lymphocytic leukemia. Semin Hematol 2007;44:246-251 (Pubitemid 47599542)
27. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 1996;124:311-315 (Pubitemid 26047457)
28. Galligan L, Catherwood MA, Morris TCM, Kettle P, Drake M, Alexander HD. Association between gender and age at presentation and molecular markers of disease progression in B-CLL. Leuk Lymphoma 2007;48Suppl 1.
29. Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005;46:553-560 (Pubitemid 40584871)
30. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-1999
31. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001;86:8-12.